Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)

Annals of Oncology ◽

10.1093/annonc/mdw376.19 ◽

2016 ◽

Vol 27 ◽

pp. vi334 ◽

Cited By ~ 2

Author(s):

J. Guigay ◽

E. Chamorey ◽

P. Céruse ◽

F. Mornex ◽

M. Degardin ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Observational Study ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Dose Intensity ◽

Line Treatment ◽

First Line ◽

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Annals of Oncology ◽

10.1016/j.annonc.2021.10.142 ◽

2021 ◽

Vol 32 ◽

pp. S1432

Author(s):

D.A. Colevas ◽

K. Misiukiewicz ◽

A.T. Pearson ◽

J. Fayette ◽

J.R. Bauman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.791652823 ◽

2012 ◽

Author(s):

Marco Merlano

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.14726100 ◽

2011 ◽

Author(s):

Jan Vermorken

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

90TiP FRAIL-IMMUNE: A multicenter, prospective, single arm phase II of the combination of durvalumab with carboplatin and paclitaxel as first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy (GORTEC 2018-03)

Annals of Oncology ◽

10.1093/annonc/mdz449.043 ◽

2019 ◽

Vol 30 ◽

pp. xi32

Author(s):

J. Fayette

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

Standard Chemotherapy ◽

Modified docetaxel, cisplatin and fluorouracil therapy as a first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e17503 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e17503-e17503

Author(s):

Nebi Serkan Demirci ◽

Sercan Aksoy ◽

Nuriye Özdemir ◽

Taner Babacan ◽

Gokmen Umut Erdem ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Head And Neck Cancer ◽

Retrospective Study ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

Cetuximab + platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An observational study (ENCORE)

Annals of Oncology ◽

10.1093/annonc/mdy287.013 ◽

2018 ◽

Vol 29 ◽

pp. viii377

Author(s):

C. Le Tourneau ◽

M. Ghiani ◽

M.C. Cau ◽

R. Depenni ◽

G. Ronzino ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Observational Study ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study

Current Medical Research and Opinion ◽

10.1080/03007995.2016.1257984 ◽

2016 ◽

Vol 33 (3) ◽

pp. 401-407 ◽

Cited By ~ 5

Author(s):

Nebi Serkan Demirci ◽

Sercan Aksoy ◽

Nuriye Yıldırım Özdemir ◽

Gökmen Umut Erdem ◽

Melike Ozcelik ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Head And Neck Cancer ◽

Retrospective Study ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

New first-line treatment for recurrent or metastatic squamous cell carcinoma of head and neck: does one size fit all?

Therapeutic Radiology and Oncology ◽

10.21037/tro.2020.03.02 ◽

2020 ◽

Vol 4 ◽

pp. 5-5

Author(s):

Naomi Kiyota ◽

Yoshinori Imamura

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.14726135 ◽

2011 ◽

Author(s):

Pol Specenier

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽